Business · Companies · 1 hr ago
Weight-loss drugs prompt Australia’s food industry to rethink meals
Australia has approved two weight-loss pills as use of GLP-1 medicines grows.
The pills are Eli Lilly’s Foundayo and Novo Nordisk’s Wegovy, following a market that so far has mainly offered weekly injections.
These medicines reduce appetite and weight, and their growing use could affect a country where 67 per cent of adults are overweight or obese.
But users may face nutritional deficiencies and muscle loss, and experts warn that eating too little without professional guidance can raise the risk of malnutrition.
Australia’s food and grocery businesses are responding to a potential market of 7 million users within a decade, an estimate cited in the story.
They are considering smaller meals with more protein and fibre, while restaurants may offer smaller entrees and larger plates of meat to share.
The Wegovy pill is due to go on sale on Friday, while Foundayo is expected to be available in the coming days.
Australia’s food and grocery businesses are reconsidering meals, prices and portion sizes as use of GLP-1 weight-loss drugs grows.
The medicines reduce appetite and weight, but users may face higher risks of nutritional deficiency and muscle loss.
The article says meals for users are likely to be smaller, filling and higher in protein and fibre.
Two weight-loss pills were approved by Australia’s medicine regulator this month.
An industry estimate cited in the article says GLP-1 users could reach 7 million adults within a decade.
- Who
- Australian food and grocery businesses are responding to the growth of GLP-1 weight-loss drugs.
- What
- The industry is considering changes to food offerings, prices and portion sizes.
- When
- The trend is underway; two weight-loss pills were approved this month.
- Where
- Australia.
- Why
- The drugs reduce appetite, changing how much and what users eat, and businesses want to serve this growing market.
This story does not have two clearly opposing sides.
Australia’s medicine regulator approved Eli Lilly’s Foundayo and Novo Nordisk Pharmaceuticals’ Wegovy pills.
Wegovy was due to become available for sale.
Eli Lilly said Foundayo would become available.
- Excess weight in Australia
- 14.6 million people; 67 per cent of adults and 27 per cent of children
- Potential GLP-1 market
- An estimate cited in the article says 7 million adults, or 30 per cent of adults, within a decade
- Marley Spoon sales
- 12 per cent are “GLP-1 support” meals
- High-protein food shoppers
- 28 per cent of Australians, according to Sunrice
- Sunrice product
- Protein+ Rice contains 10 grams of protein via beef-derived collagen peptides
What people are saying
Every chef wants to please the diner and see flavours savoured, and clean plates sent back to the kitchen.
You get full on much less food than before, so every mouthful counts when you’re on these drugs.
I suspect we may look back on their impact on society and say it’s been one of the most significant changes in a long time.